ISSN: 2634-9221
European Journal of Applied Sciences; Vol. 14 No. 03 (2026) (11-31)
https://doi.org/10.14738/ejas.1403.1282

Medical and Nonmedical Uses of Cannabis: Overview of Cannabis in Egypt

Tarek Mohamed Heikal

1. Narcotics, Ergogenics and Poisons Department, Medical Research and Clinical Studies Institute, National Reseach Centre, Dokki, Cairo, Egypt

Abstract: The medical use of cannabis is extending across many countries. Some of them legalize its use clearly and others require licensure systems to approve treatment for eligible patients. Despite this growing interest and utilization, there remains a lack of solid scientific evidence supporting its medical use, even though cannabis has been used therapeutically for thousands of years. The aim of the following conduct is to present updated data on the potential roles of cannabis-based treatments regulations globally including Egypt against various illness conditions. The information highlighted that incorporating cannabis into the therapeutic system may offer benefits. However, in many cases, despite encouraging perspectives and outcomes, the supporting evidence remains insufficient and requires further validation. Due to social and legal barriers, the conduct of such rigorous clinical trials has been hindered, limiting the availability of high-quality evidence to guide medical practice.

Keywords: Cannabis, Autoimmunity, Inflammation, Therapy, Recreation, Legalization.

INTRODUCTION

Cannabis genus belongs to the plant family Cannabaceae. Within this genus, there are several species, including Cannabis sativa, Cannabis indica, and Cannabis ruderalis. It was highly valued in ancient civilizations for its versatility, serving as a source of food (hemp seeds), fiber for textiles and rope, and as a medicinal and psychotropic agent [1,2]. It is also facing significant legal and social challenges over time [3-5].

Cannabis is a pharmacologically complex plant containing hundreds of organic compounds, including cannabinoids (also known as phytocannabinoids), terpenoids, flavonoids, polyphenols, phenolic acids, tocopherols, fatty acids, and other secondary metabolites. These constituents contribute to the diverse effects and therapeutic properties of cannabis, both individually and through their interactions [6-9].

Cannabinoids are unique to cannabis, with at least one hundred identified in the plant. The most studied and principal cannabinoids are Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) [6-8, 10-14].

Cannabinoids, the active compounds in cannabis, have demonstrated immunosuppressive and immunomodulatory properties. They can suppress autoreactive lymphocytes and T cell functions induce functional regulatory T cell (Treg), and modulate inflammation through the endocannabinoid system (ECS) [15-18]. In animal models, CB2 agonists have enhanced Treg differentiation and suppressed disease activity in inflammatory bowel disease [15]. These properties have led to interest in cannabinoids as potential therapies for autoimmune diseases, with particular attention to their anti-inflammatory and analgesic effects [17, 18].

THC is the main psychoactive constituent, responsible for effects such as euphoria, relaxation, heightened sensory perception, laughter, and altered perception of time. It is also associated with adverse effects, including cognitive impairment, dependency, anxiety, psychosis-like symptoms, and exacerbation of psychiatric conditions, especially in adolescents. Its medical uses include reducing pain, spasticity, nausea, and increasing appetite in patients with anorexia or wasting syndrome in AIDS [7, 8, 10-13].

CBD is nonpsychoactive and has demonstrated anxiolytic, antipsychotic, antibacterial, antioxidant, anticancer, antiemetic, and anti-inflammatory properties. It may offset some of the negative effects of THC, such as anxiety and psychosis-like symptoms. It is often used for self-medication in anxiety and may have therapeutic effects in epilepsy and pain modulation [7, 8, 10, 13, 14]. Other cannabinoids under study include cannabinol, cannabichromene, and tetrahydrocannabivarin [8]. The ratio of THC to CBD varies among cannabis species and strains, with some strains (e.g., "skunk") being high in THC and low in CBD [7].

Terpenoids and flavonoids are significant secondary metabolites in cannabis. Terpenoids, such as beta-caryophyllene, have demonstrated pharmacological effects, including inhibition of gastric lesions in animal models. Terpenes can bind and activate cannabinoid receptors and may contribute to the overall effects of cannabis [8, 8, 19]. Flavonoids, including flavocannabiside, are also present and may contribute to the pharmacological profile of cannabis [9, 19].

MODE OF ACTION

Cannabis is consumed through various modes, including smoking (with or without tobacco), vaping/vaporizing, and oral ingestion via edibles or drinkable products [20-23]. The mode of administration can influence both the onset and intensity of effects, as well as health outcomes [21,23,24]. It exerts its effects primarily through interaction with cannabinoid receptors (CB1 and CB2) which are distributed throughout the body [25]. CB1 receptors are primarily located in the brain and spinal cord, where they play roles in pain relief, memory, movement, and the regulation of gut activity. In contrast, CB2 receptors are detected in many other tissues including the immune system and are less well understood. Both CB1 and CB2 receptors are expressed on immune cells, which can also synthesize, secrete, transport, and catabolize cannabinoids [26]. The discovery and cloning of these receptors in the brain clarified the mode of action of cannabis extracts and led to the identification of endogenous cannabinoids (endocannabinoids) such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG). These compounds, along with phytocannabinoids from the plant, modulate various physiological processes [25, 27].

THC Acts mainly on CB1 and CB2 receptors, producing psychoactive effects and influencing pain, mood, appetite, and other functions [20,25]. It acts as a partial agonist on CB1 endocannabinoid receptors distributed across several brain regions. While CBD exact mechanism in epilepsy is unclear, it does not significantly affect CB1 or CB2 receptors. Suggested modes of action include antagonism of GPR55 in the thalamus, modulation of voltage-gated sodium and calcium channels, and agonism of serotonin (5-HT1A) receptors [28]. It has shown neuroprotective effects in animal models of Parkinson’s disease and can counteract oxidative stress [22].

METABOLISM OF CANNABIS

Cannabis metabolism is a multifaceted process involving absorption, distribution, hepatic metabolism, and excretion, with significant variability depending on the route of administration, frequency of use, and individual physiological and environmental factors. Its metabolism involves complex processes affecting various organs, primarily the liver, and is mediated by the endocannabinoid system (ECS), which includes neurotransmitters and receptors that respond to both endogenous and exogenous cannabinoids. The ECS plays a significant role in neurodevelopment, cognition, memory, motivation, arousal, sleep, pain, and immune processes, and is crucial for maintaining homeostasis by modulating neurotransmitter levels at the presynaptic nerve level [29-31].

The main metabolism of THC occurs in the liver, primarily via cytochrome P450 enzymes (CYP2C and CYP3A). THC undergoes Phase I metabolism, including hydroxylation to form active metabolites such as 11-hydroxy-THC (11-OH-THC) and 8-hydroxy-THC (8-β-OH-THC), followed by further oxidation to the inactive metabolite 11-carboxy-THC (THC-COOH) [32-35].

11-hydroxy-THC is more potent than THC and readily crosses the blood-brain barrier, potentially with greater brain penetrance than THC itself. In contrast, THC-COOH lacks cannabimimetic effects and is primarily excreted as a glucuronide conjugate [32, 34]. However, CBD metabolism is hydroxylated by CYP450 enzymes to the active metabolite 7-OH-CBD, which is further metabolized to the inactive 7-COOH-CBD. CBD also undergoes direct glucuronidation via UGTs [36].

THC is highly lipophilic, distributing rapidly to organs with high blood supply (brain, heart, liver) and later to adipose tissues. Chronic use leads to accumulation in fat-rich tissues, with gradual release and prolonged detectability in bio-samples [37].

Cannabis consumption leads to changes in perception and mood, increased heart rate, lowered blood pressure, and impairment of memory, psychomotor coordination, and concentration.

Long-term effects are less clear, and chronic use may result in toxic effects on organs such as the brain, heart, liver, and kidneys, as well as alterations in body mass index, redox balance, and glycemic status [38, 39]. There are slight discrepancies in reported excretion rates, with some sources stating 65% of the dose is eliminated in feces and 20% in urine, while others report 40% in feces and 30% in urine [32,40]. The number of metabolites identified after cannabis administration varies, with some sources mentioning about 20 metabolites and others stating almost 100 metabolites have been identified, especially after oral administration [34, 35].

In general, Cannabis pharmacokinetics is complex and highly variable, influenced by route of administration, formulation, individual factors, and genetic background. Both pharmacokinetic and pharmacodynamic drug–drug interactions are possible, primarily mediated by CYP450 enzymes and transporter proteins. There remain significant gaps in knowledge regarding the pharmacokinetics of many cannabis products, especially in special populations and with novel administration routes, underscoring the need for further research and individualized therapeutic approaches [41-43].

NONMEDICAL USES OF CANNABIS

The minimum amount of THC required for perceptible psychoactive effects is about 10 µg/kg body weight [38]. Nonmedical cannabis use is characterized by several main routes of administration, including smoking joints (with or without tobacco), using water pipes (with or without tobacco), and oral ingestion through food or tea. While joint smoking remains the most prevalent method, alternative routes such as water pipes and ingestion are increasingly popular among youth. Despite this trend, few studies have directly compared the health effects of different administration routes in nonmedical users, whereas such comparisons are more common in research on medical cannabis use. Additionally, cannabis use encompasses methods such as vaporizing and vaping, and individuals may use non-prescribed cannabis for reasons including pleasure-seeking, coping with difficult situations, self-medicating, and appetite control [44, 45].

Nonmedical cannabis use is often motivated by factors such as pleasure, coping with stress, self-medication, and appetite regulation. The distinction between medical and nonmedical use is sometimes blurred [46,47]. A long-term follow-up study found that Swedish males who consumed cannabis by age 18 were diagnosed with schizophrenia at a rate 2.4 times higher than non-users. Others reported adverse effects include anxiety, depression, psychosis, bronchitis, lung cancer, arrhythmia, and myocardial infarction. Acute complications are primarily cardiovascular and respiratory in nature [47]. However, in studies of the older general public, no significant beneficial physical or mental health outcomes were reported from adjusted analyses, except possibly reduced future incidence of head/neck and prostate cancers. Harmful outcomes were more prevalent than beneficial ones in randomized controlled trials and cohort studies. It is important to note that associations from cross-sectional and sequential studies do not establish causality, and cannabis use may be more common among individuals with pre-existing health conditions [46-48]. Cannabis for therapeutic purposes without formal medical authorization cases are classified as nonmedical when reports indicate recreational use or lack information about therapeutic indications [45, 49].

MEDICAL USES OF CANNABIS THERAPY

Medical cannabis (MC) is most commonly used for the management of chronic pain, but it is also employed in the treatment of other conditions such as mental health disorders (anxiety, depression, PTSD), sleep disorders, dementia, movement disorders (dystonia, dyskinesias, Tourette syndrome), multiple sclerosis spasticity, seizures (including Dravet syndrome and Lennox-Gastaut syndrome), glaucoma, cachexia, and appetite stimulation in patients suffering from anorexia and wasting syndromes 48, 50-53]. It has also been explored for the management of several autoimmune diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), dermatomyositis, lupus, and Sjogren's syndrome [54-57]. Its use is primarily focused on symptom relief, such as spasticity, pain, and bladder dysfunction in MS, and quality-of-life improvements in IBD [15, 57,58].

As Multiple Sclerosis (MS) Therapy

MS is a persistent neuroinflammatory autoimmune disease that affects the human central nervous system and is driven by autoreactive T lymphocytes which attack myelin. This

inflammatory process results in the disruption of the blood-brain barrier leading to activation of macrophage and T cell, and increased production of cytokines and cytotoxic proteins, including metalloproteinases [59].

Cannabis use is common among people with multiple sclerosis (MS), with surveys indicating that over 40% to more than half of individuals with MS have used or are currently using cannabis, and nearly half have considered or tried it for symptom relief [60-63]. Many patients begin using cannabis after their MS diagnosis, often seeking relief from symptoms such as pain, spasticity, mood swings, and sleep disturbances [60,61]. However, only a small proportion of users (as low as 4% to 21%) receive medical cannabis prescriptions, with the majority using cannabis without professional guidance [61,63]. Cannabis use in MS is also associated with recreational drug experiences and tobacco smoking, and individuals with such backgrounds may be at greater risk of becoming dependent users [61,64].

MC are approved for treating spasticity in MS, with studies showing small but significant improvements in spasticity, pain, and bladder dysfunction [15,52,57,58]. Beyond spasticity, cognitive impairment is a critical concern in MS. Cognitive dysfunction already affects approximately 20 %–40 % of patients with relapsing-remitting MS and up to 70 %–80 % of those with secondary progressive MS [65,66]. Observational data indicates that MS patients who smoke MC show further deterioration in processing speed, memory, and executive functioning [67,68]. This reinforced concerns MC may adversely affect cognition in people with MS, who already suffer from high rates of cognitive dysfunction associated with the disease. It should be noted that there was heterogeneity in study design and outcomes, making definitive conclusions difficult.

Multiple studies, including randomized controlled trials and systematic reviews, have found that cannabis-based medicines may be effective in reducing chronic pain and spasticity in MS, with some evidence suggesting an effect magnitude comparable to standard pain medications [69-71]. Patients frequently report high efficacy of cannabis in relieving pain and spasticity, and some have reduced their use of prescription medications after starting cannabis [62, 63,70].

In general, cannabis is widely used among people with MS, primarily for symptom management of spasticity, pain, and bladder dysfunction, with many patients reporting subjective benefits [60, 61, 63]. However, chronic use is associated with cognitive risks and other adverse effects, and most users do not receive medical supervision [61, 68, 72]. The current evidence base is limited, and further high-quality, long-term studies are needed to clarify the benefits and risks of cannabis and cannabinoid products in MS [68, 73]. Result Set Now, submit each query to Google and record the first 50 results. This way, the result set of 10 queries become 500 results.

AS Inflammatory Bowel Disease (IBD) Therapy

IBD, immune-mediated inflammatory disease with rheumatologic manifestations, includes Crohn’s disease and ulcerative colitis, distinguished by specific clinical, radiological, endoscopic, and histological findings. The exact cause remains partially unclear, but it is believed to involve a multifactorial complex interplay of genetic predisposition, environmental factors, microbiota imbalance, and dysregulated immune responses.

Many studies have found connections between the ECS and IBD, but clinical trials report no significant benefit or adverse effects from MC for IBS symptoms [57, 58]. However, patients have reported improvements in quality-of-life scores, despite the lack of objective symptom improvement [57].

In addition, preclinical studies demonstrate that cannabinoid receptor agonists, particularly those targeting CB2, reduce inflammation, whereas receptor antagonism or genetic knockout in animal models is associated with increased inflammatory responses [74, 75]. This generated optimism regarding a potential role for MC in management of IBD, which includes both Crohn's and ulcerative colitis.

Significant resources have been invested in trying to realize the therapeutic potential of MC in managing IBD. Research in Clinical Gastroenterology and hepatology explored the mechanisms by which cannabinoids may modulate gut inflammation and detailed how cannabinoids can influence the gut microbiome and the immune system [76].

In-vivo studies have shown that activation of cannabinoid receptors can exert anti-inflammatory effects and may contribute to ameliorating colitis symptoms [77]. CB1 receptors, in particular, have been implicated in protecting against hyperstimulation of immune cells that occurs during IBD. Through this mechanism, THC may alleviate IBD symptoms, primarily diarrhea, and help control inflammation [76, 78]. Activation of CB2 receptors has been shown to induce apoptosis and reduce the proliferation of T cells. Additionally, it decreases the recruitment of neutrophils, T cells, and macrophages to the inflamed colon [79].

In summary, while MC appears to improve IBD symptoms, particularly pain and quality of life, objective evidence of anti-inflammatory or disease-modifying effects is lacking. Existing studies are small, short- term, or observational, with safety concerns emerging in long-term use. Larger, rigorously designed randomized controlled trials with robust clinical and endoscopic endpoints are necessary before cannabinoids can be recommended as standard therapy for IBD.

As Rheumatoid Arthritis (RA) Therapy

Cannabis-based medicines have been recognized for their potential in RA and other inflammatory diseases, though the supporting evidence remains insufficient and requires further validation [17, 18, 55, 56].

Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation and progressive joint destruction, driven by proinflammatory cytokines (IL-1, TNF-α, IL-6), which promote matrix metalloproteinase activity and cartilage destruction [80]. It is among the most prevalent autoimmune rheumatic disorders and is a leading cause of disability globally.

Preclinical index supports a potential role for the endocannabinoid receptors (CB1/CB2) in modulating inflammation in RA. CB1 and CB2 receptors are expressed in synovial tissue, and their activation has been shown to downregulate proinflammatory cytokine release and fibroblast proliferation. Also, preclinical studies, including those evaluating selective CB2 agonists, have elucidated reductions in joint inflammation and tissue damage [81]. However, the ligands were detected in synovial fluid from RA and osteoarthritis patients but not in healthy controls, suggesting disease-specific dysregulation,

the synovial fluid of RA patients contains CB1, CB2 receptors, anandamide (AEA), and 2-arachidonoylglycerol (2-AG), which are absent in healthy individuals. It was also demonstrated that cannabinoid receptor stimulation led to the phosphorylation of the cellular kinases ERK-1 and ERK-2 in fibroblast- like cells from RA and osteoarthritis patients, this effect was inhibited when the cells were exposed to the CB1 antagonist [81, 82].

Further investigation and cultivation of synovial cells obtained from RA patients showed that CBD increased intracellular calcium levels, reduced cell viability and IL-6/IL-8/MMP-3 production by activating transient receptor potential ankyrin 1 channel and mitochondrial targets. This effect was enhanced by TNF-α suggesting CBD preferentially targets activated, pro-inflammatory rheumatoid arthritis synovial fibroblast [82].

In contrast to MS, clinical evidence for MC use in RA is even more limited. The only randomized controlled trial to date, conducted by Blake et al. (2006, n =58), evaluated MC over 5 weeks in RA patients with refractory pain. The study reported modest reductions in pain and improved sleep quality but no significant changes in disease activity scores [83]. In this context, systematic reviews of cannabinoids for pain, including in RA populations, have reached similar conclusions and found modest analgesic benefits with frequent, generally mild adverse effects such as dizziness and fatigue [84, 85].

In summary, MC may provide at times symptomatic relief and in preclinical model may provide anti-inflammatory effects, but translation into clinical benefit is unproven. Human data consist largely of small, short-term trials and uncontrolled surveys, making conclusions about efficacy, safety, and disease modification premature.

As Systemic Sclerosis (SSc) Therapy

Systemic sclerosis (SSc) is a multisystem autoimmune disease recognized by fibrosis of visceral organs and skin, as well as vascular damage. The disease is categorized into subtypes based on the extent of skin involvement. Complications in the heart, lungs, and kidneys are common, particularly in diffuse SSc, and these complications significantly contribute to increased morbidity and mortality [82].

Preclinical studies suggest potential antifibrotic effects. In murine models, cannabidiol (CBD) reduced skin and liver fibrosis and decreased immune cell infiltration [86]. (Similarly, the CB2 agonist JWH-133 reduced fibroblast proliferation, collagen accumulation, and pulmonary fibrosis in mice [87]. Emerging preclinical work has identified “compound 66”. This is a selective cannabinoid type-2 receptor agonist with potent anti-fibrotic activity. Designed through structure–activity relationship optimization of pyrazole-3-carboxamide derivatives, compound 66 was shown to reduce dermal inflammation, fibrosis, and profibrotic marker expression in bleomycin-induced skin fibrosis in mice [88]. While mechanistically compelling, these results derive entirely from animal models, which do not fully replicate the heterogeneity of human SSc.

Reviews have summarized potential benefits, particularly for pain relief and modulation of fibrotic processes [33]. The review highlighted potential symptomatic relief, particularly in pain reduction and modulation of fibrotic processes, but noted the lack of large-scale, high-quality clinical trials. In 2020, a review specifically on cannabidiol (CBD) concluded that while CBD may reduce inflammation and pain, clinical evidence remains limited [57]. However, these reviews consistently emphasize the lack of high- quality

clinical trials, underscoring that the majority of evidence remains preclinical. Translation of antifibrotic findings from animal models to human disease has historically been poor, and outcomes such as organ involvement, survival, or quality of life have never been systematically studied in cannabinoid trials for SSc. A 2021 preclinical study investigated cannabinoid therapy in fibrotic disease models, including SSc, and found that cannabinoids could reduce fibrosis and inflammation in animal models. It emphasized the need for human clinical trials to validate the findings [89].

Human evidence is extremely limited. A Phase II clinical trial evaluated lenabasum, a synthetic CB2 receptor agonist, not a THC/CBD extract, showing preliminary safety and efficacy signals in SSc [90]. The study was small, lacked long-term follow-up, and did not report robust endpoints such as organ function or survival, making conclusions tentative at best. Moreover, lenabasum is not MC but a synthetic CB2 receptor agonist.

In summary, while preclinical studies strongly suggest antifibrotic and anti-inflammatory effects, clinical evidence in SSc is scarce. Current human data are limited to small early-phase trials, insufficient to establish efficacy or safety. Until adequately powered randomized studies are conducted, cannabinoids in SSc should be considered experimental, with potential limited to symptomatic pain relief rather than disease modification.

As Fibromyalgia Therapy

The diagnosis of fibromyalgia comprises diffuse chronic pain, tender points at specific locations, uncomfortable sleep, fatigue and various cognitive difficulties and is only clinical as no objective biomarkers or imaging findings exist. These symptoms frequently overlap with other rheumatic, endocrinological, and psychiatric conditions, so the diagnosis is more challenging [91]. Given its strong correlation with pain, sleep disturbance, and fatigue, MC has gained attention as a potential therapeutic option [85]. A review by Albo and Amital through international prescription drug monitoring programs revealed marked increase in MC prescribing for chronic pain, particularly in fibromyalgia, reflecting both patient demand and physician willingness to consider MC as an alternative to opioids in complex pain syndromes [92]. Similarly, Singla et al. reported symptom improvement in 82 % of respondents, with remarkable effects on pain, anxiety, and sleep disturbances [93]. While valuable for capturing patient experience, such surveys are vulnerable to recall bias, lack control groups, and often recruit from self-selected populations of cannabis users, limiting generalizability.

Randomized evidence is emerging but remains limited. A Brazilian double-blind, placebo-controlled trial found significant improvement in Fibromyalgia Impact Questionnaire scores with THC-rich oil compared to placebo [94]. In contrast, a small, single-dose, randomized crossover trial by Van de Donk et al. (2019; n =20) showed limited short-term analgesia, highlighting the need for larger and longer trials [95].

Systematic reviews, including a 2018 meta analysis of 16 studies, found MC demonstrated moderate efficacy in for chronic pain conditions, including fibromyalgia [96]. It assessed both randomized controlled trials (RCTs) and observational studies. It concluded that while cannabinoids showed moderate efficacy in reducing pain intensity, the results were most significant for chronic pain conditions such as fibromyalgia. The conclusion was

based on the fact that MC did not consistently provide long-term benefits, and adverse effects such as dizziness and sedation were common.

A 2024 editorial by David et al. [97] emphasized the increasing interest in cannabinoids within rheumatology, particularly for chronic pain conditions such as fibromyalgia, while underscoring the need for more robust clinical evidence. These findings align with broader research suggesting that cannabinoids may provide relief for fibromyalgia-related symptoms, although larger controlled studies are still needed.

Overall, MC appears to provide symptomatic relief in subsets of fibromyalgia patients, particularly for pain and sleep disturbance. However, the current evidence base is limited by small sample sizes, short follow-up, reliance on patient-reported outcomes, and lack of standardized dosing or formulations. Robust, adequately powered RCTs are needed to establish long-term efficacy and safety.

As Diabetes Therapy

Previous studies have demonstrated that cannabis users have a modestly lower prevalence of both obesity and diabetes compared to matched controls, despite cannabis's appetite-stimulating effects and increased consumption of low-nutritional-value carbohydrates among users [98, 99]. However, these findings are subject to potential confounders such as the "well smoker effect," recall bias, relatively low cannabis exposure in survey populations and no dose-response effect has been demonstrated. In contrast, other studies have not consistently supported a protective association; for example, a Swedish prospective study found no change in diabetes incidence between cannabis smokers and non-smokers after adjusting for age [100].

Cannabinoids may influence diabetes and glucose control through several mechanisms. Stimulation of CB1 receptors in pancreatic beta cells can cause beta cell death, while activation in the brain and fat cells can increase appetite and promote adipogenesis and obesity, which are risk factors for glucose intolerance and type 2 diabetes [3, 101]. Human and animal studies have shown that cannabis use is associated with higher caloric intake, but paradoxically, users tend to have lower body mass index (BMI), lower prevalence of obesity, and reduced insulin resistance and fasting insulin levels [98, 99]. Also, its use is associated with higher glycated hemoglobin (HbA1c) and a greater incidence of diabetic ketoacidosis in type 1 diabetes, as well as evidence of poorer self-management during episodes of use [47, 102-104]. Some studies suggest that the beneficial impact of cannabis on insulin resistance may be mediated through its effect on lowering BMI rather than a direct metabolic effect [98]. While animal models have suggested a protective effect of cannabis against type 1 diabetes, these findings have not been replicated in humans [47].

Cannabis use among individuals with type 2 diabetes has increased, with a 34% rise in past-month use among U.S. adults with diabetes between 2021 and 2022 [102, 105]. There are also concerns about the joint effects of type 2 diabetes and cannabis use on mental health, including an elevated risk of suicide, which is paradoxical given the metabolic associations [105].

CBD and THC are the main cannabinoids in cannabis, and both may have anti-diabetic effects through their action on the endocannabinoid system [101, 106, 107]. However, detailed mechanisms remain unclear, and only one randomized controlled trial has

investigated CBD's efficacy on glycemic parameters in type 2 diabetes, finding no effect on lowering glycemic parameters despite some changes in other markers [106]. Preclinical studies in rodents have shown that CBD can arrest the onset and progression of diabetes and ameliorate some complications, but these findings have not been confirmed in humans [106, 107]. CBD's anti-inflammatory properties may be valuable in treating and delaying diabetes symptoms, as chronic inflammation is a risk factor and symptom of both type 1 and type 2 diabetes[107].

The literature on cannabis and diabetes is limited, with many studies being cross-sectional, based on self-report, or lacking in mechanistic detail [47, 106]. There are gaps in direct evidence linking cannabis use to improved or worsened outcomes in diabetes, and more high-quality research is needed to provide robust, evidence-informed guidance for patients and healthcare providers [104]. Current recommendations emphasize education, counseling, and caution regarding recreational cannabis use in people with diabetes, especially type 1 diabetes [102, 104].

As Mental Health Disorder Therapy

Medical cannabis is increasingly being used to manage a variety of mental health conditions, including anxiety, depression, post-traumatic stress disorder (PTSD), stress, insomnia, mood stabilization, and attention-deficit/hyperactivity disorder (ADHD) [57, 108-112]. While chronic pain remains the most common reason for medical cannabis use, mental health disorders are frequently cited as secondary or emerging indications [51, 57, 108, 109, 111, 112].

Anxiety is consistently reported as the most common mental health condition for which medical cannabis is used [57, 109, 111]. Depression and PTSD are also prominent reasons for medical cannabis authorization [57, 109, 112]. Other reported uses include management of stress, insomnia, mood stabilization, and ADHD [110, 112]. Both prescribed and self-administered cannabis are used for mental health symptom management, often alongside chronic pain and sleep disorders [51, 112, 113].

SAFETY PROFILE AND ADVERSE EFFECTS

Cannabinoids generally have a high safety profile for acute toxicity, but chronic use has been associated with negative effects on reproductive performance, including hypofertility [55].

Common side effects include dizziness, cognitive impairment, and nausea [58]. The psychoactive effects and addictive potential of Δ9-THC have historically limited clinical use, while CBD is well tolerated and lacks abuse liability [17].

While adverse effects associated with medical and recreational cannabis use include neural and psychiatric disorders, as well as increased risk of other conditions such as neoplasia [111, 113, 114]. There is a strong association between cannabis use and the onset or worsening of mental disorders such as schizophrenia, bipolar disorder, depression, anxiety attacks, panic disorders, and dependence [111, 113, 114].

LEGAL STATUS OF MEDICAL CANNABIS (MC)

MC authorization has been associated with an increased risk of emergency department visits or hospitalization for depressive disorders, highlighting the need for careful risk-benefit assessment, especially for patients seeking cannabis for depression [114]. Frequent cannabis users are more likely to have anxiety disorders, and patients with anxiety disorders have a higher risk of developing cannabis dependence [111]. In addition, the lack of rigorous clinical trials, small sample sizes, and legal/social barriers have hindered the accumulation of high-quality evidence [16, 57, 112]. However, the evidence supporting its efficacy is often described as limited, weak, or conflicting, with systematic reviews and clinical studies reporting mixed outcomes [16, 56, 57, 112].

Legal Status of cannabis for medical use varies significantly across countries and within countries, often creating a complex and sometimes contradictory regulatory environment. In the United States, cannabis is classified as a Schedule I substance under federal law, making its possession and use illegal at the federal level. However, many states have enacted their own laws permitting the use of cannabis for medical purposes, resulting in a patchwork of regulations. As of recent data, 36 to 38 states, several territories, and the District of Columbia have legalized cannabis for medical use, while 24 states and some territories have also legalized it for recreational use. Despite these state-level legalizations, federal law supersedes state law, and individuals may still face federal prosecution even in states where medical cannabis is legal [30, 50, 54, 115].

Other countries also display a range of legal frameworks. For example, Canada has legalized cannabis for both medical and recreational purposes, though there are restrictions such as minimum age requirements that vary by province. In the United Kingdom, medical cannabis can be prescribed by specialist consultants under specific conditions, but general practitioners are not permitted to prescribe it. Across the European Union, laws differ: some countries allow only cannabis-derived medications, while others have more permissive policies. In India, the legal status of cannabis varies by state, with some states allowing medical use under certain conditions and others maintaining strict prohibitions [46, 54, 115].

CANNABIS USES IN EGYPT

Historical Medical Use of Cannabis in Egypt

Evidence from ancient Egyptian medical papyri, such as the Ebers Papyrus (circa 1550 BCE), documents the use of cannabis for treating a variety of medical ailments, including inflammation, glaucoma, pain, eye diseases, and gynecologic disorders. Cannabis was also mentioned for topical application as an anti-inflammatory compound and as a remedy for depression and ophthalmic disorders in other ancient Egyptian texts, such as the Papyrus Ramesseum III (1700 BCE)[69, 116, 117]. Hemp threads have been found in Egyptian tombs, indicating its use as a source of fiber over 3300 years ago [116, 117].

However, there is conflicting information regarding the cultivation of cannabis in ancient Egypt, with one source stating that cannabis was neither cultivated nor known in Ancient Egypt [118].

while other sources suggest its presence and use [69, 116, 117].

Current Legal Status of Cannabis in Egypt

Cannabis is rigorously forbidden in Egypt, and its legal status is among the strictest in Africa. While some African countries have legalized or decriminalized cannabis for medical or traditional use, Egypt maintains strict prohibition [69]. Despite this, cannabis farming is partially authorized in Egypt, with cultivation occurring especially in the Sinai Peninsula and Upper Egypt. Hashish is commonly smuggled into the country, while herbal cannabis (bango) is increasingly cultivated domestically [118=120]. Cannabis is included in Schedule IV of the United Nations' Single Convention on Narcotic Drugs, which allows for medical and scientific use under a licensing system, but Egypt has not adopted such a system for medical cannabis [115].

Prevalence and Patterns of Use

Cannabis is the most abused drug in Egypt, with approximately 2.7%–4.9% of the population aged 15–64 years having used cannabis at least once in their lifetime. It is particularly prevalent among youth and drivers, often due to the belief that it is harmless [119, 121]. The main forms of cannabis abused in Egypt are bango (herbal cannabis) and hashish, with seizures of these substances increasing since 1998, possibly reflecting higher market demand or more effective law enforcement [118 119]. Drug abuse in Egypt is mainly a male problem between 20 and 30 years of age, although female abusers are increasing [121, 122].

Medical Use and Regulatory Framework

Currently, there is no legal framework for the medical use of cannabis in Egypt. Unlike countries such as Israel, the Netherlands, and several others where medical cannabis is regulated and available under prescription, Egypt has not legalized cannabis for medical purposes [69, 115]. The Egyptian government has focused on prevention and treatment of addiction, with clinics and treatment centers established for drug addicts, and educational programs aimed at young people [118]. The regulatory challenges in Egypt include strict prohibition, lack of product standardization, and absence of a system for medical cannabis access, contrasting with evolving frameworks in other countries [115, 123].

Comparison with Other Countries

Legalization and Regulation: Countries such as Israel, the Netherlands, the UK, and South Africa have legalized or regulated medical cannabis, with detailed criteria for licensure and prescription [53]. In contrast, Egypt maintains strict prohibition, with no legal access for medical use [69, 115, 118].

Cultivation and Market

While cannabis farming is partially authorized in Egypt, it is not regulated for medical use. Lebanon and Morocco, other Arab nations with high prevalence rates, have moved towards legalization for medical and industrial purposes, with Lebanon legalizing cannabis for medical use in 2020 [120]. Therapeutic Evidence: There is a strong consensus in the

literature supporting the therapeutic use of cannabis for conditions such as chronic pain, epilepsy, and cancer, which has led to re-evaluation of its legal status in many countries. However, Egypt has not adopted these changes [115, 123, 124].

CONCLUSION

Cannabis is one of the most widely used psychoactive substances globally, with over 192 million people reporting some level of usage in 2020, and nearly 1 in 10 individuals using it daily. Approximately the same proportion develops addictive symptomatology. Cannabis is the most commonly used drug worldwide, with particularly high use in North America, where 14.5% of the population reports use and 13.8 million adults are daily or near-daily users. As of 2020, 47 states in the US have medical cannabis programs, although cannabis remains a federally designated schedule I controlled substance. The World Health Organization estimates that about 2.5% (147 million) of the adult population worldwide uses cannabis for recreational or other reasons [125, 126, 127].

REFERENCES

[1]. Laaboudi FZ, Rejdali M, Salhi A, Elyoussfi A, Talhaoui A, Amhamdi H, Ahari MH. Bibliometric analysis of beneficial cannabis research: performance analysis and science mapping from 2012 to 2022 and focus on Morocco. Toxicology Reports. 2024 Dec 1;13:101713.

[2]. Greydanus DE, Nazeer A, Patel DR. Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS. Disease-a-Month. 2025 Jan 13:101853.

[3]. Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, Marotto D, Ceribelli A, Ablin JN, Hauser W. Medical cannabis and cannabinoids in rheumatology: where are we now?. Expert review of clinical immunology. 2019 Oct 3;15(10):1019-32.

[4]. Elias A, Rosado C, do Céu Costa M. Study on knowledge and perceptions on the uptake of non-medicinal cannabis-substances and preparations by Portuguese consumers: Borderline issues. Heliyon. 2024 Dec 30;10(24).

[5]. Muñoz E, Solis E, Mitchell S. Cannabis Use in Pregnancy and Postpartum: Understanding the Complicated History and Current Recommendations to Facilitate Client-Centered Discussions. Advances in Family Practice Nursing. 2023 May 1;5(1):151-68.

[6]. Ladha KS, Mistry N, Wijeysundera DN, Clarke H, Verma S, Hare GM, Mazer CD. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. Cmaj. 2021 Sep 7;193(35):E1377-84.

[7]. Nethengwe M, Maphosa Y, Ahiante BO, Oyenihi AB. Cannabis for medicine and food: A benefit vs risk critical appraisal. South African Journal of Botany. 2024 Dec 1;175:15-31.

[8]. Savage, S. R., Romero-Sandoval, A., Schatman, M., Wallace, M., Fanciullo, G., McCarberg, B., & Ware, M. (2016). Cannabis in pain treatment: Clinical and research considerations. The Journal of Pain. 2016 17(6), 654–668.

[9]. Pattnaik, F., Nanda, S., Kumar, V., Naik, S., Dalai, A.K. and Mohanty, M.K. Extraction of sugars and cellulose fibers from cannabis stems by hydrolysis, pulping, and bleaching. Chemical Engineering & Technology. 2022 Jan 45(5), pp.962-970.

[10]. Platt, B., Kamboj, S., Morgan, C.J. and Curran, H.V., 2010. Processing dynamic facial affect in frequent cannabis-users: evidence of deficits in the speed of identifying emotional expressions. Drug and Alcohol Dependence, 112(1-2), pp.27-32.

[11]. Duperrouzel, J.C., Granja, K., Pacheco-Colón, I. and Gonzalez, R., 2020. Adverse effects of cannabis use on neurocognitive functioning: A systematic review of meta-analytic studies. Journal of dual diagnosis, 16(1), pp.43-57.

[12]. Daniju, Y., Faulkner, P., Brandt, K. and Allen, P., 2022. Prefrontal cortex and putamen grey matter alterations in cannabis and tobacco users. Journal of Psychopharmacology, 36(12), pp.1315-1323.

[13]. Wycoff, A.M., Metrik, J. and Trull, T.J., 2018. Affect and cannabis use in daily life: A review and recommendations for future research. Drug and alcohol dependence, 191, pp.223-233.

[14]. De Aquino, J.P., Sherif, M., Radhakrishnan, R., Cahill, J.D., Ranganathan, M. and D'Souza, D.C., 2018. The psychiatric consequences of cannabinoids. Clinical therapeutics, 40(9), pp.1448-1456.

[15]. Kerage, D., Sloan, E.K., Mattarollo, S.R., and Mccombe, P.A., 2019. Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology 332, p. 99-111.

[16]. Michaeli, I., Lassman, S., Halpert, G., Jacob, G. and Amital, H., 2025. Exploring therapeutic potential of Cannabis based therapy in autoimmune and rheumatic disorders. Autoimmunity Reviews, p.103925.

[17]. Furgiuele, A., Cosentino, M., Ferrari, M. and Marino, F., 2021. Immunomodulatory potential of cannabidiol in multiple sclerosis: A systematic review. Journal of Neuroimmune Pharmacology, 16(2), pp.251-269.

[18]. Gonçalves, E.D. and Dutra, R.C., 2019. Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?. Drug discovery today, 24(9), pp.1845-1853.

[19]. Abdel-Salam, O., 2016. Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids. Asian Pacific journal of tropical medicine, 9(5), pp.413-419.

[20]. Gruber, S.A., Sagar, K.A., Dahlgren, M.K., Racine, M.T., Smith, R.T. and Lukas, S.E., 2016. Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. Frontiers in pharmacology, 7, p.355.

[21]. Fischer, B. and Albrecht, H.J., 2024. Developments in cannabis enforcement practices and patterns associated with non-medical cannabis legalization policies: a basic literature/data review. Journal of Crime and Justice, pp.1-11.

[22]. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V. and Mechoulam, R., 2009. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in pharmacological sciences, 30(10), pp.515-527.

[23]. Chen, S., Tang, H., Tang, L., Yang, W., Xing, S., Jie, S., Ruan, G. and Wang, W., 2025. The Origin, Domestication, and Global Spread of Cannabis (Cannabis sativa). International Journal of Molecular Evolution and Biodiversity, 15.

[24]. Streck, J.M., Regan, S., Bearnot, B., Gupta, P.S., Kalkhoran, S., Kalagher, K.M., Wakeman, S. and Rigotti, N.A., 2022. Prevalence of cannabis use and cannabis route of administration among Massachusetts adults in buprenorphine treatment for opioid use disorder. Substance use & misuse, 57(7), pp.1104-1110.

[25]. Dhir, A., 2018. Cannabidiol in refractory epilepsy. Studies in Natural Products Chemistry, 58, pp.419-438.

[26]. Katchan, V., David, P. and Shoenfeld, Y., 2016. Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity reviews, 15(6), pp.513-528.

[27]. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M. and Maccarrone, M., 2013. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in lipid research, 52(4), pp.633-650.

[28]. Orsolini, L., Chiappini, S., Volpe, U., De Berardis, D., Latini, R., Papanti, G.D. and Corkery, J.M., 2019. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina, 55(9), p.525.

[29]. Camilleri, M. and Zheng, T., 2023. Cannabinoids and the gastrointestinal tract. Clinical Gastroenterology and Hepatology, 21(13), pp.3217-3229.

[30]. Hunt, D.A., Keefe, J., Whitehead, T. and Littlefield, A., 2020. Understanding cannabis. The Journal for Nurse Practitioners, 16(9), pp.645-649.

[31]. Dahlgren, M.K., Lambros, A.M., Smith, R.T., Sagar, K.A., El-Abboud, C. and Gruber, S.A., 2022. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Communications medicine, 2(1), p.139.

[32]. Castro-Navarro, I., McGuire, M.A., Williams, J.E., Holdsworth, E.A., Meehan, C.L. and McGuire, M.K., 2024. Maternal cannabis use during lactation and potential effects on human milk composition and production: a narrative review. Advances in Nutrition, 15(4), p.100196.

[33]. Shah, P.A., Patil, R. and Harrison, S.A., 2023. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology, 77(1), pp.323-338.

[34]. Wiley, C.D. and Campisi, J., 2021. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nature metabolism, 3(10), pp.1290-1301.

[35]. Narkowicz, S., Płotka, J., Polkowska, Ż., Biziuk, M. and Namieśnik, J., 2013. Prenatal exposure to substance of abuse: a worldwide problem. Environment international, 54, pp.141-163.

[36]. Wermer, K., Korbacska-Kutasi, O., Berkecz, R., Csupor, D., Ágh, N., Sztojkov-Ivanov, A. and Cserhalmi, D., 2025. Pharmacokinetics of cannabidiol and its two main phase I metabolites in Connemara ponies. Frontiers in Veterinary Science, 12, p.1599934.

[37]. Pearlson, G.D., Stevens, M.C. and D'Souza, D.C., 2021. Cannabis and driving. Frontiers in psychiatry, 12, p.689444.

[38]. Shamloul, R. and Bella, A.J., 2011. Impact of cannabis use on male sexual health. The journal of sexual medicine, 8(4), pp.971-975.

[39]. Siwar, M.A.A., Mansour, S.H.E.D., Aldubayan, M.A., Alhowail, A.H., Almogbel, Y.S. and Emara, A.M., 2023. Health status outcome among cannabis addicts after treatment of addiction. Plos one, 18(11), p.e0290730.

[40]. Thomas-Brown, P.G.L., Martin, J.S., Sewell, C.A., Abel, W.D. and Gossell-Williams, M.D., 2018. Risperidone provides better improvement of sleep disturbances than haloperidol therapy in schizophrenia patients with Cannabis-Positive urinalysis. Frontiers in Pharmacology, 9, p.769.

[41]. Manca, A., Valz, C., Chiara, F., Mula, J., Palermiti, A., Billi, M., Antonucci, M., De Nicolo, A., Luxardo, N., Imperiale, D. and Vischia, F., 2024. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM. Biomedicine & Pharmacotherapy, 175, p.116686.

[42]. Ilan, Y., 2022. Digital medical cannabis as market differentiator: Second-generation artificial intelligence systems to improve response. Frontiers in Medicine, 8, p.788777.

[43]. Foster, B.C., Abramovici, H. and Harris, C.S., 2019. Cannabis and cannabinoids: kinetics and interactions. The American journal of medicine, 132(11), pp.1266-1270.

[44]. Baggio, S., Deline, S., Studer, J., Mohler-Kuo, M., Daeppen, J.B. and Gmel, G., 2014. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. Journal of Adolescent Health, 54(2), pp.235-240.

[45]. Haddad, R., Dagenais, C., Fallu, J.S., Huỳnh, C., D'Arcy, L. and Hot, A., 2024. Facilitators of and obstacles to practitioners' adoption of harm reduction in cannabis use: a scoping review. Harm Reduction Journal, 21(1), p.178.

[46]. Rohit, K.G., Ruchi, P., Itishree, D. and Sapana, K., 2024. Regulatory challenges on cannabis: Concern, advantages, and disadvantages. In Cannabis and its Derivatives (pp. 307-333). Academic Press.

[47]. Dasgupta, S., 2021. Cannabinoid receptors: A potential target for osteoporosis pain. International Journal of Pharmaceutical Research, 13(3).

[48]. Ng, J.Y., Tahir, U. and Lum, N., 2022. The quality of health information provided on web sites selling cannabis to consumers in Canada is poor. Harm Reduction Journal, 19(1), p.138.

[49]. Plebon-Huff, S., Aziz, N., Cavar, M., Hassan, S., Aoun, M., Perwaiz, S. and Abramovici, H., 2025. Trends in cannabis adverse reaction reports: A descriptive analysis of spontaneous reporting data submitted to the Canada Vigilance Program since legalization and regulation of cannabis for non-medical purposes in Canada. Journal of Cannabis Research, 7(1), p.56.

[50]. Rabgay K, Waranuch N, Chaiyakunapruk N, Sawangjit R, Ingkaninan K, Dilokthornsakul P., 2020. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: a systematic review and network meta-analysis. J Am Pharm Assoc. 60(1),p. 225–34 https://doi. org/10.1016/j.japh.2019.07.015.

[51]. Senator, B., Pardal, M. and Vandam, L., 2025. Evidence synthesis of medical cannabis research: current challenges and opportunities. European Archives of Psychiatry and Clinical Neuroscience, 275(2), pp.293-305.

[52]. Gherzi, M., Milano, G., Fucile, C., Calevo, M.G., Mancardi, M.M., Nobili, L., Astuni, P., Marini, V., Barco, S., Cangemi, G. and Manfredini, L., 2020. Safety and pharmacokinetics of medical cannabis preparation in a monocentric series of young patients with drug resistant epilepsy. Complementary Therapies in Medicine, 51, p.102402.

[53]. Sokratous, S., Mpouzika, M., Kaikoushi, K., Alexandrou, G. and Karanikola, M., 2023. Attitudes, beliefs, and knowledge regarding medical cannabis among healthcare students in the Republic of Cyprus: a cross-sectional descriptive correlational study. Frontiers in Psychiatry, 14, p.1196915.

[54]. Nayak, P., Pantvaidya, G., Ranganathan, P., Jiwnani, S., Joshi, S. and Gogtay, N.J., 2023. Clinical studies with Cannabis in India–A need for guidelines for the investigators and ethics committees. Perspectives in Clinical Research, 14(3), pp.146-151.

[55]. Greco, A., Del Prete, C., De Biase, D., Palumbo, V., Albanese, S., Bruzzese, D., Carotenuto, D., Ciani, F., Tafuri, S., Meomartino, L. and Mancini, M., 2021. Effects of oral administration of Lepidium meyenii on morphology of mice testis and motility of epididymal sperm cells after tetrahydrocannabinol exposure. Frontiers in Veterinary Science, 8, p.692874.

[56]. Hoch, E., Volkow, N.D., Friemel, C.M., Lorenzetti, V., Freeman, T.P. and Hall, W., 2025. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European archives of psychiatry and clinical neuroscience, 275(2), pp.281-292.

[57]. Lee, C., Eurich, D.T. and Dyck, J.R., 2023. The use of medical cannabis: A focus on Canada—Cannabis, Cannabinoids, and Endocannabinoids. In Medicinal Usage of Cannabis and Cannabinoids (pp. 63-75). Academic Press.

[58]. McNabb, M., Durante, K.A., Trocchio, S., Ritter, D.J., MacCaffrie, R., Brum, A., Mandile, S. and White, S., 2023. Self-reported medicinal cannabis use as an alternative to prescription and over-the-counter medication use among US military veterans. Clinical Therapeutics, 45(6), pp.562-577.

[59]. Dendrou, C.A., Fugger, L. and Friese, M.A., 2015. Immunopathology of multiple sclerosis. Nature Reviews Immunology, 15(9), pp.545-558.

[60]. AlHabil, Y., Saadeddin, L., Ishkirat, H., Alqam, M., Hossoon, O., Hameedi, S., Yacoub, H., Yasin, D., Bahbah, A., Oweidat, M. and Mosa, H., 2025. Assessing the Role of Cannabis in Managing Spasticity in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Clinical Therapeutics.

[61]. Pilloni, G., Pehel, S., Ko, T., Kreisberg, E., Sammarco, C., Charlson, R.E. and Charvet, L., 2025. The unmet need for cannabis use disorder treatment in multiple sclerosis: Insights from a nationwide pilot study. Multiple Sclerosis and Related Disorders, 98, p.106443.

[62]. Kindred, J.H., Li, K., Ketelhut, N.B., Proessl, F., Fling, B.W., Honce, J.M., Shaffer, W.R. and Rudroff, T., 2017. Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation. Complementary therapies in medicine, 33, pp.99-104.

[63]. Gustavsen, S., Søndergaard, H.B., Andresen, S.R., Magyari, M., Sørensen, P.S., Sellebjerg, F. and Oturai, A.B., 2019. Illegal cannabis use is common among Danes with multiple sclerosis. Multiple sclerosis and related disorders, 33, pp.5-12.

[64]. Wingerchuk, D., 2004. Cannabis for medical purposes: cultivating science, weeding out the fiction. The Lancet, 364(9431), pp.315-316.

[65]. Sadigh-Eteghad S, Farhoudi M, Naseri A, Seyedi-Sahebari S, Ahmadi M, Sadeghi- Bazargani H, et al. Cognitive impairment in multiple sclerosis: a population-based study from Iran. J Clin Neurol 2021;17(1):113–20.

[66]. Portaccio E, Amato MP. Cognitive impairment in multiple sclerosis: an update on assessment and management. NeuroSci 2022;3(4):667–76.

[67]. Ghaffar, O. and Feinstein, A., 2008. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology, 71(3), pp.164-169.

[68]. Landrigan, J., Bessenyei, K., Leitner, D., Yakovenko, I., Fisk, J.D. and Prentice, J.L., 2022. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. Multiple sclerosis and related disorders, 57, p.103338.

[69]. Riaz, T. and Akram, M., 2024. Cannabis in pain management. Cannabis and Khat in Drug Discovery, pp.475-487.

[70]. Jarvis, S., Rassmussen, S. and Winters, B., 2017. Role of the endocannabinoid system and medical cannabis. The Journal for Nurse Practitioners, 13(8), pp.525-531.

[71]. Martinez, J.E. and Guimarães, I., 2024. Fibromyalgia–are there any new approaches?. Best Practice & Research Clinical Rheumatology, 38(1), p.101933.

[72]. Friedman, D., French, J.A. and Maccarrone, M., 2019. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. The Lancet Neurology, 18(5), pp.504-512.

[73]. Chetia, S. and Borah, G., 2020. Δ 9-Tetrahydrocannabinol toxicity and validation of cannabidiol on brain dopamine levels: an assessment on cannabis duplicity. Natural Products and Bioprospecting, 10(5), pp.285-296.

[74]. Miller, A.M. and Stella, N., 2008. CB2 receptor-mediated migration of immune cells: it can go either way. British journal of pharmacology, 153(2), pp.299-308.

[75]. Pertwee, R.G., 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British journal of pharmacology, 156(3), pp.397-411.

[76]. Izzo, A.A., Muccioli, G.G., Ruggieri, M.R. and Schicho, R., 2015. Endocannabinoids and the digestive tract and bladder in health and disease. Endocannabinoids, pp.423-447.

[77]. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B.F., Ferri, G.L., Sibaev, A., Storr, M. and Lutz, B., 2004. The endogenous cannabinoid system protects against colonic inflammation. The Journal of clinical investigation, 113(8), pp.1202-1209.

[78]. Izzo, A.A. and Sharkey, K.A., 2010. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & therapeutics, 126(1), pp.21-38.

[79]. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10□/□mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 2012 Jan 15;258(2):256–67.

[80]. Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2), 183-196.

[81]. Richardson, D., Pearson, R.G., Kurian, N., Latif, M.L., Garle, M.J., Barrett, D.A., Kendall, D.A., Scammell, B.E., Reeve, A.J. and Chapman, V., 2008. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis research & therapy, 10(2), p.R43.

[82]. Lowin, T., Tingting, R., Zurmahr, J., Classen, T., Schneider, M. and Pongratz, G., 2020. Cannabidiol (CBD): A killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell death & disease, 11(8), p.714.

[83]. Blake, D.R., Robson, P., Ho, M., Jubb, R.W. and McCabe, C.S., 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45(1), pp.50-52.

[84]. Frane, N., Stapleton, E., Iturriaga, C., Ganz, M., Rasquinha, V. and Duarte, R., 2022. Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. Journal of cannabis research, 4(1), p.47.

[85]. Fitzcharles MA, Buchbinder R, Ostermann G, Cameron M. Cannabis use in fibromyalgia: a survey of patients. J Rheumatol 2018;45(3):504–10.

[86]. Del Río, C., Ruiz-Pino, F., Prados, M.E., Fiebich, B.L., Tena-Sempere, M. and Muñoz, E., 2022. Cannabidiol markedly alleviates skin and liver fibrosis. Frontiers in Pharmacology, 13, p.981817.

[87]. Servettaz, A., Kavian, N., Nicco, C., Deveaux, V., Chéreau, C., Wang, A., Zimmer, A., Lotersztajn, S., Weill, B. and Batteux, F., 2010. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. The American journal of pathology, 177(1), pp.187-196.

[88]. Zhou L, Yang X, Li W, Zhang H, Liu Y, Zhang T, et al. Discovery of compound 66 as a selective cannabinoid type 2 receptor agonist with anti-fibrotic properties in systemic sclerosis. Eur J Pharmacol 2021;890:173666.

[89]. Garcia P, Lopez M, others. Cannabinoid therapy in preclinical models of fibrotic diseases: implications for systemic sclerosis. Pharmacol Res 2021;163:105225.

[90]. Spiera, R., Khanna, D., Kuwana, M., Furst, D.E., Frech, T.M., Hummers, L., Stevens, W., Matucci-Cerinic, M., Baron, M., Distler, O. and Dgetluck, N., 2021. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and experimental rheumatology, 39(4), pp.S124-S133.

[91]. Lichtenstein, A., Tiosano, S., Comaneshter, D., Amital, H., Cohen, A.D. and Amital, D., 2018. Cross-sectional analysis of the associations between fibromyalgia and diabetes mellitus. Reumatologia/Rheumatology, 56(5), pp.275-278.

[92]. Albo, B. and Amital, H., 2025. The Complex Interplay of Prescription Drug Monitoring Programs, Regulated Medical Cannabis, and Chronic Pain Healthcare Visits. Journal of General Internal Medicine, 40(5), pp.1028-1029.

[93]. Singla, A., Anstine, C.V., Huang, L., Rosedahl, J.K., Mohabbat, A.B. and Philpot, L.M., 2024, April. A cross-sectional survey study of cannabis use for fibromyalgia symptom management. In Mayo Clinic Proceedings (Vol. 99, No. 4, pp. 542-550).

[94]. Chaves, C., Bittencourt, P.C.T. and Pelegrini, A., 2020. Ingestion of a THC-rich cannabis oil in people with fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial. Pain medicine, 21(10), pp.2212-2218.

[95]. Van De Donk, T., Niesters, M., Kowal, M.A., Olofsen, E., Dahan, A. and Van Velzen, M., 2019. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain, 160(4), pp.860-869.

[96]. Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., Radbruch, L., Häuser, W. and Conrad, R., 2018. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of cachexia, sarcopenia and muscle, 9(2), pp.220-234.

[97]. David P, Mohsen A, Amital H. Is medical Cannabis a solution for controlling fibromyalgia symptoms?. In: Mayo Clinic Proceedings; 2024. p. 524–6.

[98]. Bryan, A.D., Skrzynski, C.J., Giordano, G., Yang, J., Stanger, M., Bidwell, L.C., Hutchison, K.E. and Perreault, L., 2025. Cannabis use is associated with less peripheral inflammation but similar insulin sensitivity as non-use in healthy adults. The American Journal of Medicine.

[99]. YorkWilliams, S.L., Gust, C.J., Mueller, R., Bidwell, L., Hutchison, K.E., Gillman, A.S. and Bryan, A.D., 2019. The new runner's high? Examining relationships between cannabis use and exercise behavior in states with legalized cannabis. Frontiers in Public Health, 7, p.443163.

[100]. Pastor, A., Conn, J., MacIsaac, R.J. and Bonomo, Y., 2020. Alcohol and illicit drug use in people with diabetes. The lancet Diabetes & endocrinology, 8(3), pp.239-248.

[101]. Suttithumsatid, W., Shah, M.A., Bibi, S. and Panichayupakaranant, P., 2022. α-Glucosidase inhibitory activity of cannabidiol, tetrahydrocannabinol and standardized cannabinoid extracts from Cannabis sativa. Current Research in Food Science, 5, pp.1091-1097.

[102]. Kaminski, N.E. and Kaplan, B.L., 2021. Immunomodulation by cannabinoids: Current uses, mechanisms, and identification of data gaps to be addressed for additional therapeutic application. In Advances in Pharmacology (Vol. 91, pp. 1-59). Academic Press.

[103]. Sexton, T.R. and Alshaarawy, O., 2020. Cannabis use prevalence among individuals with diabetes: The National Survey on Drug Use and Health, 2005–2018. Drug and alcohol dependence, 212, p.108035.

[104]. Karakus, K.E., Akturk, H.K., Snell-Bergeon, J.K. and Shah, V.N., 2025. Progression of diabetic retinopathy after initiation of automated insulin delivery system in adults with type 1 diabetes. Journal of Diabetes Science and Technology, p.19322968251318740.

[105]. Dhruva, Y., Messias, E. and Lin, P.I., 2025. Glucagon-like peptide-1 receptor agonists and suicide risk in individuals with diabetes and Cannabis use disorder. Preventive Medicine Reports, p.103244.

[106]. Ma, L., Hettema, J.M., Cousijn, J., Bjork, J.M., Steinberg, J.L., Keyser-Marcus, L., Woisard, K., Lu, Q., Roberson-Nay, R., Abbate, A. and Moeller, F.G., 2021. Resting-state directional connectivity and anxiety and depression symptoms in adult cannabis users. Biological psychiatry: cognitive neuroscience and neuroimaging, 6(5), pp.545-555.

[107]. Merrill, R.M., Ashton-Hwang, K. and Gallegos, L., 2024. Association between cannabis use and physical activity in the United States based on legalization and health status. Journal of Cannabis Research, 6(1), p.39.

[108]. Lucas, P., Baron, E.P. and Jikomes, N., 2019. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm reduction journal, 16(1), p.9.

[109]. Sachedina, F., Chan, C., Damji, R.S. and de Sanctis, O.J., 2022. Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study. Psychiatry research, 313, p.114573.

[110]. Pathak, S., Jeyabalan, J.B., Liu, K., Cook, P., Lange, B., Kim, S., Nadar, R., Ward, K., Alexander, C.S.W., Kumar, A. and Dua, K., 2024. Assessing effects of Cannabis on various neuropathologies: A systematic review. Journal of Ayurveda and Integrative Medicine, 15(3), p.100911.

[111]. Leung, J., Stjepanović, D., Dawson, D. and Hall, W.D., 2021. Do cannabis users reduce their THC dosages when using more potent cannabis products? A review. Frontiers in psychiatry, 12, p.630602.

[112]. Berger, M., Li, E. and Amminger, G.P., 2020. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports CP, 13(10), p.e235307.

[113]. Mills, E., 2025. Harmonizing cannabis and environmental policy. International Journal of Drug Policy, 143, p.104923.

[114]. Yana, J.L., Lee, C., Eurich, D.T., Dyck, J.R., Hanlon, J.G. and Zongo, A., 2023. Risk of depressive disorders associated with medical cannabis authorization: a propensity score matched cohort study. Psychiatry research, 320, p.115047.

[115]. Samanta, D., 2019. Cannabidiol: a review of clinical efficacy and safety in epilepsy. Pediatric neurology, 96, pp.24-29.

[116]. Pearlson, G., 2020. Weed science: cannabis controversies and challenges. Academic Press.

[117]. Pant, S.P., Joshi, S., Bisht, D. and Bisht, M., 2024. Exploring the historical, botanical, and taxonomical foundations of cannabis: A review. Cannabis and its Derivatives, pp.3-36.

[118]. Abdel-Salam, O.M.E., Galal, A.F., Elshebiney, S.A. and Gaafar, A.E.D.M., 2017. International aspects of cannabis use and misuse: Egypt. In Handbook of Cannabis and Related Pathologies (pp. 110-121). Academic Press.

[119]. Souleman, A.M., Gaafar, A.E.D.M., Abdel-Salam, O.M. and ElShebiney, S.A., 2017. Determination of delta-9-tetrahydrocannabinol content of cannabis seizures in Egypt. Asian Pacific Journal of Tropical Medicine, 10(3), pp.311-314.

[120]. Sabalbal, A., Eid, M., Kobeissy, F.H., Baroud, E. and El Hayek, S., 2025. Cannabis use among Arab students: a systematic review. Frontiers in Psychiatry, 16, p.1511563.

[121]. Oraby, D., 2013. Harm reduction approach in Egypt: the insight of injecting drug users. Harm Reduction Journal, 10(1), p.17.

[122]. Khedr, E.M., Elserogy, Y. and Ahmed, G.K., 2025. The Impact of Cannabis Use on Cortical Excitability and Inhibitory Mechanisms: A Case-Control Study. Psychiatry Research, p.116617.

[123]. Debbarma, G. and Acharya, P.C., 2024. Cannabis and its derivatives: Guide to medical application and regulatory challenges. In Cannabis and its Derivatives (pp. 37-91). Academic Press.

[124]. Castle, R.D., Marzolf, J., Morris, M. and Bushell, W.C., 2025. Meta-analysis of medical cannabis outcomes and associations with cancer. Frontiers in Oncology, 15, p.1490621.

[125]. Madsen, H.J., Carmichael, H., Reinicke, T., Gleisner, A.L., Del Chiaro, M., Schulick, R.D. and Stewart, C.L., 2023. Cannabis use and post-operative complications in patients undergoing pancreatic resection. HPB, 25(4), pp.431-438.

[126]. Kulkarni, K.R., Schafer, M., Berner, L.A., Fiore, V.G., Heflin, M., Hutchison, K., Calhoun, V., Filbey, F., Pandey, G., Schiller, D. and Gu, X., 2023. An interpretable and predictive connectivity-based neural signature for chronic cannabis use. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 8(3), pp.320-330.

[127]. Szaflarski, J.P. and Bebin, E.M., 2014. Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. Epilepsy & Behavior, 41, pp.277-282.